If You Invested $10,000 In AbbVie Stock 10 Years Ago, How Much Would You Have Now?

AbbVie Inc. ABBV discovers, develops, manufactures and sells pharmaceuticals worldwide.

It is set to report the Q4 2024 earnings on Jan. 31 before the market opens. Wall Street analysts expect the company to post an EPS of $2.98, up from $2.79 in the year-ago period. According to Benzinga Pro, quarterly revenue is expected to reach $14.81 billion, up from $14.30 billion in the previous year.

If You Bought AbbVie Stock 10 Years Ago

The company's stock traded at approximately $63.10 per share 10 years ago. If you had invested $10,000, you could have bought roughly 158 shares. Currently, shares trade at $170.30, meaning your investment's value could have grown to $26,989 from stock price appreciation alone. However, AbbVie also paid dividends during these 10 years. 

Don't Miss:

• Unlock the hidden potential of commercial real estate — This platform allows individuals to invest in commercial real estate offering a 12% target yield with a bonus 1% return boost today!
• This Jeff Bezos-backed startup will allow you to become a landlord in just 10 minutes, with minimum investments as low as $100.

AbbVie's dividend yield is currently 3.85%. Over the last 10 years, it has paid about $44.05 in dividends per share, which means you could have made $6,981 from dividends alone. 

Summing up $26,989 and $6,981, we end up with the final value of your investment, which is $33,970. This is how much you could have made if you had invested $10,000 in AbbVie stock 10 years ago. This means a total return of 239.7%. However, this figure is less than the S&P 500 total return for the same period, which was 242.69%.

Trending: It’s no wonder Jeff Bezos holds over $70 million in art — this alternative asset has outpaced the S&P 500 since 1995, delivering an average annual return of 11.4%. Here’s how everyday investors are getting started.

What Could The Next 10 Years Bring? 

AbbVie has a consensus rating of "Buy" and a price target of $192.13 based on the ratings of 36 analysts. The price target implies a nearly 13% potential upside from the current stock price.

On Oct. 30, the company announced Q3 2024 earnings, posting an adjusted EPS of $3.00, up from $2.95 a year ago, beating the consensus of $2.92, as reported by Benzinga.

Net revenues reached $14.46 billion, up 3.8%, beating the consensus of $14.28 billion. Sales were up 4.9% on an operational basis.

See Also: Commercial real estate has historically outperformed the stock market, and this platform allows individuals to invest in commercial real estate with as little as $5,000 offering a 12% target yield with a bonus 1% return boost today!

AbbVie raised its 2024 adjusted EPS guidance to $10.90-$10.94 from prior guidance of $10.67-$10.87 compared to consensus of $10.85, which includes an unfavorable impact of 64 cents per share related to acquired IPR&D and milestones expense incurred year-to-date through the third quarter 2024.

Check out this article by Benzinga, which unpacks the latest options trading trends in AbbVie.

Given the expected upside potential of 13%, growth-focused investors may find AbbVie stock attractive. Furthermore, they can benefit from the company's solid dividend yield of 3.85%.

Wondering if your investments can get you to a $5,000,000 nest egg? Speak to a financial advisor today. SmartAsset’s free tool matches you up with up to three vetted financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you.

A 9% Return In Just 3 Months

EquityMultiple's ‘Alpine Note — Basecamp Series' is turning heads and opening wallets. This short-term note investment offers investors a 9% rate of return (APY) with just a 3 month term and $5K minimum. The Basecamp rate is at a significant spread to t-bills. This healthy rate of return won't last long. With the Fed poised to cut interest rates in the near future, now could be the time to lock in a favorable rate of return with a flexible, relatively liquid investment option. 

What's more, Alpine Note — Basecamp can be rolled into another Alpine Note for compounding returns, or into another of EquityMultiple's rigorously vetted real estate investments, which also carry a minimum investment of just $5K. Basecamp is exclusively open to new investors on the EquityMultiple platform.

Looking for fractional real estate investment opportunities? The Benzinga Real Estate Screener features the latest offerings.